Kalorama Information has published a new market research report, “DNA Sequencing Equipment and Services Markets,” which examines the companies developing and selling new sequencing technologies. The report includes revenue forecasts to 2012, profiles of companies in the market, and an overview of new technologies under development. The report costs $3,500. Further information is available here.
Epicentre Biotechnologies has released the mScript mRNA Production System, a kit that includes an in vitro transcription system, capping enzymes, and RNA poly(A) tailing reagents, for producing transfection, electroporation, or microinjection-ready mRNA.
The Wellcome Trust Sanger Institute’s Cancer Genome Project has released version 30 of the COSMIC (Catalog of Somatic Mutations in Cancer) database. COSMIC release 30 includes full literature curations of five additional tumor suppressor genes: MEN1, ATM, CYLD, FBXW7, and WTX. In addition, the database includes two new CGP resequencing studies, which adds 91 new genes to COSMIC and brings its total to 3,302.
GlobalOptions Group’s Bode Technology unit has released the Bode Crime Scene Collector for collecting and processing DNA samples at crime scenes. The product is pre-labeled and designed for easy packaging in order to reduce the number of manipulations performed and minimize the chances of evidence contamination.
Clinical Data’s Cogenics division has begun offering sequencing services based on the 454 Genome Sequencer FLX system installed at its facility in Meylan, France. The company signed an agreement to purchase the 454 system from Roche two months ago (see In Sequence 04-03-07).
“We have already attracted new customers for the first projects on the platform and we have a strong pipeline of current and new customer interest in 454 FLX sequencing as a companion to traditional automated Sanger sequencing,“ said Robert Bondaryk, senior vice president and general manager of Cogenics, in a statement.